Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.